

Sleep Patterns and the Risk of Acute Stroke

Results From the INTERSTROKE International Case-Control Study

Christine Eileen Mc Carthy, MSc, Salim Yusuf, DPhil, Conor Judge, PhD, Alberto Alvarez-Iglesias, PhD, Graeme J. Hankey, MBBS, MD, FRACP, Shahram Oveisgharan, MD, Albertino Damasceno, MD, Helle Klingenberg Iversen, MD, Annika Rosengren, MD, Alvaro Avezum, MD, Patricio Lopez-Jaramillo, PhD, Denis Xavier, MD, Xingyu Wang, PhD, Sumathy Rangarajan, MSc, and Martin O'Donnell, PhD, for INTERSTROKE

Correspondence

Dr. Mc Carthy
christine.mccrth@gmail.com

Neurology® 2023;100:e2191-e2203. doi:10.1212/WNL.0000000000207249

Abstract

Background and Objectives

Symptoms of sleep disturbance are common and may represent important modifiable risk factors of stroke. We evaluated the association between a spectrum of sleep disturbance symptoms and the risk of acute stroke in an international setting.

Methods

The INTERSTROKE study is an international case-control study of patients presenting with first acute stroke and controls matched by age (± 5 years) and sex. Sleep symptoms in the previous month were assessed through a questionnaire. Conditional logistic regression estimated the association between sleep disturbance symptoms and acute stroke, expressed as odds ratios (ORs) and 95% CIs. The primary model adjusted for age, occupation, marital status, and modified Rankin scale at baseline, with subsequent models adjusting for potential mediators (behavioral/disease risk factors).

Results

Overall, 4,496 matched participants were included, with 1,799 of them having experienced an ischemic stroke and 439 an intracerebral hemorrhage. Short sleep (<5 hours: OR 3.15, 95% CI 2.09–4.76), long sleep (>9 hours: OR 2.67, 95% CI 1.89–3.78), impaired quality (OR 1.52, 95% CI 1.32–1.75), difficulty getting to sleep (OR 1.32, 95% CI 1.13–1.55) or maintaining sleep (OR 1.33, 95% CI 1.15–1.53), unplanned napping (OR 1.48, 95% CI 1.20–1.84), prolonged napping (>1 hour: OR 1.88, 95% CI 1.49–2.38), snoring (OR 1.91, 95% CI 1.62–2.24), snoring (OR 2.64, 95% CI 2.17–3.20), and breathing cessation (OR 2.87, 95% CI 2.28–3.60) were all significantly associated with an increased odds of acute stroke in the primary model. A derived obstructive sleep apnea score of 2–3 (2.67, 2.25–3.15) and cumulative sleep symptoms (>5: 5.38, 4.03–7.18) were also associated with a significantly increased odds of acute stroke, with the latter showing a graded association. After an extensive adjustment, significance was maintained for most of the symptoms (not difficulty getting to/maintaining sleep and unplanned napping), with similar findings for stroke subtypes.

Discussion

We found that sleep disturbance symptoms were common and associated with a graded increased risk of stroke. These symptoms may be a marker of increased individual risk or represent independent risk factors. Future clinical trials are warranted to determine the efficacy of sleep interventions in stroke prevention.

From the Department of Medicine (C.E.M.C., C.J., A.A.-I., M.O.D.), University of Galway, Ireland; Department of Medicine (S.Y., S.R.), Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada; School of Medicine and Pharmacology (G.J.H.), Faculty of Health and Medical Sciences, University of Western Australia, Perth; Department of Medicine (S.O.), Rush Alzheimer Disease Research Center in Chicago, IL; Faculty of Medicine (A.D.), Eduardo Mondlane University, Maputo, Mozambique; Department of Neurology (H.K.I.), Rigshospitalet, University of Copenhagen, Denmark; Department of Molecular and Clinical Medicine (A.R.), University of Gothenburg and Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Medicine (A.A.), International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil; Department of Medicine (P.L.-J.), Instituto de Investigaciones MASIRA, Universidad de Santander, Bucaramanga, Colombia; Department of Medicine (D.X.), St John's Medical College and Research Institute, Bangalore, India; and Department of Medicine (X.W.), Beijing Hypertension League Institute, China.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by the authors.

Coinvestigators are listed at links.lww.com/WNL/C722.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

MORE ONLINE

 **Infographic**
links.lww.com/WNL/C794

 **CME Course**
Npub.org/cmelist

Glossary

AHEI = Alternative Healthy Eating Index; BMI = body mass index; BP = blood pressure; dCBT-I = digital cognitive behavioral therapy; ICH = intracranial hemorrhage; mRS = modified Rankin scale; OR = odds ratio; OSA = obstructive sleep apnea; PAP = positive airway pressure; SOL = sleep-onset latency; WHR = waist-to-hip ratio.

Adequate sleep is essential to health.¹ Impairments in sleep represent a spectrum of disturbance, from mild deviations in duration to impairments in different domains (quality, initiation, and maintenance), associated symptoms (napping, snoring, snorting, and breathing cessation) through to complex syndromes. While there is convincing evidence of an association between obstructive sleep apnea (OSA) and stroke, the association of other sleep disorders or impairments in sleep are less certain.² Given the high global prevalence of symptoms, the latter association, particularly, may represent an important modifiable target for population-level interventions in stroke prevention.

Prior epidemiologic studies have evaluated the association of these sleep parameters and stroke, but the methodology and results are inconsistent.³⁻¹² Most studies have incompletely measured all relevant sleep domains, which precludes a thorough understanding of their independent contribution. Certain symptoms, such as nocturnal awakening and snorting, have also been interrogated infrequently, as potential independent risk factors.^{12,13} A further limitation is that most studies have been confined to single countries, with underrepresentation of populations from many regions of the world. In the INTERSTROKE study (a large international case-control study of risk factors of stroke), we evaluated the association of different symptoms of sleep impairment, individually and cumulatively, with the risk of first acute stroke.

Methods

Population

The INTERSTROKE study is a large international case-control study of patients presenting with first stroke and matched controls. The study design has been described in detail elsewhere.¹⁴ In brief, cases were required to meet the World Health Organization clinical definition for acute stroke, were within 72 hours of admission and 5 days of current symptom onset or “last seen without deficit,” and had a CT or an MRI available or planned within 1 week of presentation. Stroke was further defined as either ischemic stroke or intracranial hemorrhage (ICH), by hour of onset and whether symptoms occurred on waking (Supplemental Section 1, links.lww.com/WNL/C721). Patients with severe stroke or aphasia (unable to communicate effectively) were included if a valid proxy respondent was available. At least 1 control, without a stroke history, was recruited for each case, from either a community or hospital/outpatient setting. Controls were matched for sex and age (± 5 years) in addition to ethnicity in countries where there was a substantial

representation from multiple ethnic groups (e.g., South Africa, Canada). A standardized questionnaire was administered by trained research staff, which collected information about known and potential risk factors. Nonfasting blood samples were collected from participants and clinical measurements (e.g., blood pressure [BP], weight) were recorded during interview and/or from the participants notes. A supplementary questionnaire addressing sleep practices in the previous month was introduced in July 2012, with implementation in consecutive patients once adopted in centers. Matched cases/controls who undertook this questionnaire were the participants of the primary analysis in this study.

Sleep Questionnaire

Specific questions asked are detailed in the eAppendix (eTable 1, links.lww.com/WNL/C721). In summary, participants were asked about sleep behaviors in the previous month (the month before stroke in cases). Areas addressed included the following: hours of nocturnal sleep duration (given in whole numbers, to the closest number of hours), sleep quality, sleep-onset latency (SOL), nocturnal awakening, sleeping during the day (both duration and whether it was planned), snoring, snorting or gasping, and breathing cessation or choking during sleep. Sleep duration categories were established for individual hour durations, truncated at <5 and >9. The reference level was set at 7 hours, based on univariate exploration of data and findings from previous research.^{15,16} The categorization of other individual sleep symptoms are detailed in the eAppendix (eTable 1). For symptoms of snoring, snorting, and breathing cessation during sleep, we derived an OSA score (range 0–3), with lower scores signifying a lower probability of sleep apnea (eTable 2). Post hoc, we also derived a summary count variable, based on the cumulative presence of sleep impairment symptoms. Termed Sleep Disturbance Symptom Burden, it included all sleep variables that were individually associated with stroke risk on univariate analysis (eTable 2). Sleep Disturbance Symptom Burden ranged from 0 to 9, with higher scores relating to greater numbers of sleep impairment symptoms.

Covariates

Further covariates of interest were determined a priori in the statistical analysis plan. Both potential confounders and potential partial mediators were selected to be included in additive models. Occupation was categorized as “house wife,” “farmer,” “laborer,” “business,” “professional,” and “other.” Marital status was defined as either “currently married or living with partner” or “separated/not currently married.” Modified Rankin scale (mRS) score at baseline was categorized as “0,” “1,” or “>1.” Alcohol consumption was

Table 1 Demographic Characteristics in Matched Cases and Controls^a

Characteristic	Cases (N = 2,243, 50%) ^b	Controls (N = 2,253, 50%) ^b	p Value ^c
Age, y	63 (14)	62 (14)	<0.001
Sex			>0.99
Female	931 (42)	935 (42)	
Male	1,312 (58)	1,318 (58)	
Region			>0.99
Western Europe/North America/Australasia	566 (25)	567 (25)	
Eastern/Central Europe/Middle East	370 (16)	370 (16)	
Africa	177 (7.9)	183 (8.1)	
South Asia	511 (23)	514 (23)	
China	408 (18)	408 (18)	
South East Asia	81 (3.6)	81 (3.6)	
South America	130 (5.8)	130 (5.8)	
Ethnicity			>0.99
European	828 (37)	832 (37)	
Chinese	407 (18)	409 (18)	
South Asian	583 (26)	584 (26)	
Other Asian	65 (2.9)	67 (3.0)	
Arab	74 (3.3)	73 (3.2)	
Latin American	125 (5.6)	126 (5.6)	
Black African	124 (5.5)	123 (5.5)	
Other African	1 (<0.1)	0 (0)	
Other	36 (1.6)	39 (1.7)	
mRS at baseline			<0.001
0	1,747 (78)	1,565 (70)	
1	360 (16)	495 (22)	
>1	135 (6.0)	190 (8.4)	
Occupation			0.007
Housewife	374 (17)	361 (16)	
Farmer	225 (10)	247 (11)	
Business	136 (6.1)	171 (7.6)	
Professional	474 (21)	531 (24)	
Laborer	793 (35)	753 (33)	
Other	240 (11)	187 (8.3)	
Marital status			<0.001
Currently married or living with partner	1,636 (73)	1,810 (80)	
Separated/not currently married	607 (27)	441 (20)	

Table 1 Demographic Characteristics in Matched Cases and Controls^a (continued)

Characteristic	Cases (N = 2,243, 50%) ^b	Controls (N = 2,253, 50%) ^b	p Value ^c
Alcohol history and frequency			<0.001
Never/former	1,551 (69)	1,606 (71)	
Low/moderate	579 (26)	593 (26)	
High intake/binge	110 (4.9)	52 (2.3)	
Smoking history			<0.001
Never or former smoker	1,601 (71)	1,759 (78)	
Current smoker	640 (29)	494 (22)	
Leisure physical activity			<0.001
Mainly inactive	1,850 (83)	1,641 (73)	
Mainly active	392 (17)	611 (27)	
Total AHEI score	22.5 (6.6)	23.4 (7.2)	<0.001
Waist-to-hip ratio	0.94 (0.09)	0.91 (0.08)	<0.001
Body mass index (kg/m ²)	26.4 (5.0)	25.8 (4.8)	<0.001
Depression			<0.001
Not sad in last 2 wk	1,671 (75)	1,820 (81)	
Sad in last 2 wk	567 (25)	430 (19)	
Global stress			<0.001
None or some periods	1,637 (73)	1,899 (84)	
Several periods or permanent	603 (27)	351 (16)	
History of hypertension or adjusted BP >140/90 mm Hg at admission	1,706 (76)	1,159 (51)	<0.001
History of diabetes or HbA1c ≥6.5%	624 (28)	405 (18)	<0.001
History of atrial fibrillation/flutter	318 (14)	68 (3.0)	<0.001
Diagnosis of obstructive sleep apnea	54 (2.4)	47 (2.1)	0.48
Subjective sleep duration, h			<0.001
<5	162 (7.2)	43 (1.9)	
5	220 (9.8)	98 (4.3)	
6	358 (16)	526 (23)	
7	486 (22)	683 (30)	
8	674 (30)	674 (30)	
9	188 (8.4)	145 (6.4)	
>9	151 (6.7)	84 (3.7)	
Self-rated overall sleep quality			<0.001
Very good	232 (10)	292 (13)	
Good	966 (43)	1,194 (53)	

Continued

Table 1 Demographic Characteristics in Matched Cases and Controls^a (continued)

Characteristic	Cases (N = 2,243, 50%) ^b	Controls (N = 2,253, 50%) ^b	p Value ^c
Fair	713 (32)	623 (28)	
Bad	238 (11)	114 (5.1)	
Very bad	88 (3.9)	26 (1.2)	
Frequency of nocturnal awakening			<0.001
Waking once or less	1,289 (58)	1,534 (68)	
Waking more than once	948 (42)	717 (32)	
Difficulty falling asleep	707 (32)	535 (24)	<0.001
Napping (duration)			<0.001
No nap	1,151 (51)	1,230 (55)	
1 h nap	700 (31)	791 (35)	
>1 h nap	389 (17)	229 (10)	
Napping, planned or unplanned			<0.001
No nap	1,152 (51)	1,226 (54)	
Unplanned nap	405 (18)	296 (13)	
Planned nap	686 (31)	731 (32)	
Snoring			<0.001
Never	726 (32)	1,013 (45)	
Do not know	182 (8.1)	115 (5.1)	
Does	1,331 (59)	1,125 (50)	
Snorting or gasping			<0.001
Never	1,397 (62)	1,839 (82)	
Do not know	276 (12)	139 (6.2)	
Does	566 (25)	275 (12)	
Breathing cessation or choking			<0.001
Never	1,531 (68)	1,918 (85)	
Do not know	286 (13)	132 (5.9)	
Does	422 (19)	203 (9.0)	

Abbreviations: AHEI = Alternative Healthy Eating Index; BP = blood pressure; HbA1c = hemoglobin A1c; mRS = modified Rankin scale.

^a Case ID-matched participants answering the supplementary questionnaire.

^b Mean (SD); n (%).

^c Wilcoxon rank sum test; Pearson χ^2 test; Fisher exact test.

categorized as “never/former,” “low/moderate,” and “high intake/binge,” whereby a weekly intake of 1–14 drinks for women and 1–21 drinks for men was determined low/moderate, and >14 drinks for women or >21 drinks for men

was determined high intake/binge.¹⁷ Leisure physical activity was categorized as “mainly active” and “mainly inactive,” with mainly active defined as moderate or strenuous leisure activity for ≥ 4 hours per week. Diet quality was defined by the modified Alternative Healthy Eating Index (AHEI).¹⁸ Waist-to-hip ratio (WHR) and body mass index (BMI) were obtained through anthropometric measurement. Depressive symptoms were determined based on the response to the question “During the last 12 months, was there ever a time when you felt sad, blue, or depressed for 2 weeks or more in a row?” Global stress was categorized as “none or some periods of stress” and “several periods or permanent stress.” Hypertension was present if the participant had a medical history of hypertension or adjusted BP of >140/90 mm Hg at admission. Diabetes was defined as a history of diabetes or a hemoglobin A1c $\geq 6.5\%$, and a history of both OSA diagnosis and atrial fibrillation/flutter were obtained.


Statistical Analysis

Demographic characteristics were described by mean values and SDs or proportions, as appropriate. Distributions were analyzed through the Kruskal-Wallis rank sum test, Pearson χ^2 test, and Fischer exact test, as appropriate.

We used univariate and multivariable conditional logistic regression analyses to determine the association of individual sleep domains with odds of acute stroke. For each sleep domain, we selected reference categories based on which category was associated with lowest odds of stroke on univariate analyses. Multivariable adjustment was conducted with additive models. Model 1 was univariate. Model 2 (primary model) was adjusted for age, marital status, occupation, and mRS at baseline. This was selected as the primary model because variables in subsequent models might include factors along the causal pathway. Model 3 was further adjusted for behavioral risk factors that might mediate risk (alcohol consumption, smoking history, leisure physical activity, AHEI score, WHR, BMI (kg/m^2), depressive symptoms, and global stress) and model 4 further adjusted for disease risk factors that might mediate risk (hypertension, diabetes, a history of atrial fibrillation/flutter, and a diagnosis of OSA). Missing information of individual models was assessed, and missing data were not imputed. These models were also completed for the association of sleep duration, OSA score, and Sleep Disturbance Symptom Burden with ICH and ischemic stroke. Excluding controls, case-case analysis was also undertaken to determine whether these sleep domains had a stronger magnitude of association with ICH, compared with ischemic stroke.

We used the Wald likelihood ratio test to test for interactions between sleep duration and other sleep parameters and sleep duration and other predefined demographic variables (age, sex, region, and ethnicity). If a significant interaction was found, subgroup/stratified analyses were undertaken for large groups ($\geq 1,000$ available in unmatched cases/

Figure 1 Odds of All Stroke, ICH, and Ischemic Stroke*



controls). Subgroup and case-case analysis were also undertaken for sleep domains (duration, OSA score, and Sleep Disturbance Symptom Burden) and hour of onset/wake-up variables. This was to observe whether the effect of sleep disturbance was influenced by the stroke onset's proximity to sleep.

Sensitivity analysis included subgroup analysis by source of control (i.e., hospital or community) and the exclusion of cases with proxy respondents. Post hoc, additional adjustment for household income was also undertaken. Statistical significance was defined as a 2-tailed p value of ≤ 0.05 . All statistical analyses were undertaken using R statistical software, version 1.3.959.¹⁹

Standard Protocol Approvals, Registrations, and Patient Consents

The INTERSTROKE study was approved by the ethics committees in all participating centers or countries, and participants (or proxy) provided written informed consent.

Data Availability

Information on the design and rationale of INTERSTROKE has been previously published.¹⁴ Individual participant data, or other documents, will not be made available now.

Results

Demographic Characteristics

Overall, there were 4,496 matched participants, including 1,799 cases with ischemic stroke and 439 cases with ICH (16.7% of the INTERSTROKE population). The number that answered questions relating to sleep domains varied minimally (eTable 3, links.lww.com/WNL/C721). Distribution of demographic, risk factor, and sleep variables in matched cases and controls are described in Table 1.

Association of Sleep Duration With Acute Stroke

In our primary multivariable model, short nocturnal sleep duration (<5 hours: odds ratio [OR] 3.15, 95% CI 2.09–4.76) and long nocturnal sleep duration (>9 hours: OR 2.67, 95% CI 1.89–3.78) were associated with an increased odds of all stroke, compared with 7 hours (reference). A significant U-shaped association persisted in all multivariable models, with similar associations found in relation to both ischemic stroke (<5 hours: OR 2.64, 95% CI 1.69–4.12; >9 hours: OR 2.68, 95% CI 1.81–3.98) and ICH (<5 hours: OR 9.12, 95% CI 2.57–32.34; >9 hours: OR 2.60, 95% CI 1.23–5.52) (Figure 1, Table 2). Odds of ICH and ischemic stroke did not differ in case-case analysis ($p > 0.4$; eTable 4, links.lww.com/WNL/C721).

Napping

Long duration (>1 hour) and unplanned napping were associated with significantly increased odds of all stroke in the primary model, while short duration (≤ 1 hour) and planned napping were not associated with an increased odds of all stroke. On further adjustment for potential mediators, napping of long duration remained significantly associated with stroke (eFigure 1, eFigure 2, links.lww.com/WNL/C721). A combined analysis of nap duration and planning are reported in Figure 2, with highest OR associated with long (>1 hour) unplanned napping (OR 2.46, 95% CI 1.69–3.57), and lowest OR associated with short (≤ 1 hour) planned napping (OR 0.91, 95% CI 0.76–1.08), in the primary model.

Sleep Quality, SOL, and Nocturnal Awakening

In our primary model, self-reported poor or fair sleep quality (OR 1.52, 95% CI 1.32–1.75), SOL (OR 1.32, 95% CI 1.13–1.55), and frequent waking (OR 1.33, 95% CI 1.15–1.53) were associated with an increased odds of acute stroke. On further adjustment for potential mediators, sleep

Table 2 Association of Sleep Duration With All Stroke, Ischemic Stroke, and ICH

The association of nocturnal sleep duration (in hours) and all stroke; odds ratio (95% CI)							
Model	<5	5	6	7	8	9	>9
Model 1 ^a	5.03 (3.47–7.30)	2.86 (2.19–3.75)	0.98 (0.81–1.18)	1.00	1.37 (1.15–1.62)	1.82 (1.40–2.37)	2.73 (1.99–3.76)
Model 2 ^b	3.15 (2.09–4.76)	2.35 (1.74–3.17)	1.03 (0.84–1.27)	1.00	1.35 (1.12–1.64)	1.59 (1.20–2.11)	2.67 (1.89–3.78)
Model 3 ^c	2.22 (1.37–3.59)	1.96 (1.39–2.75)	1.00 (0.79–1.27)	1.00	1.25 (1.02–1.54)	1.52 (1.12–2.06)	2.27 (1.58–3.27)
Model 4 ^d	1.99 (1.17–3.38)	2.06 (1.42–2.99)	0.93 (0.72–1.20)	1.00	1.24 (0.99–1.55)	1.41 (1.01–1.98)	2.14 (1.46–3.15)
The association of nocturnal sleep duration (in hours) and ischemic stroke; odds ratio (95% CI)							
Model	<5	5	6	7	8	9	>9
Model 1 ^a	4.40 (2.96–6.54)	2.65 (1.97–3.57)	0.95 (0.77–1.17)	1.00	1.38 (1.14–1.67)	1.73 (1.29–2.33)	2.57 (1.80–3.68)
Model 2 ^b	2.64 (1.69–4.12)	2.21 (1.58–3.08)	0.95 (0.75–1.20)	1.00	1.37 (1.11–1.69)	1.44 (1.04–1.99)	2.68 (1.81–3.98)
Model 3 ^c	2.05 (1.23–3.41)	1.99 (1.36–2.91)	0.92 (0.71–1.20)	1.00	1.30 (1.03–1.64)	1.37 (0.97–1.94)	2.17 (1.43–3.30)
Model 4 ^d	1.72 (0.97–3.02)	1.91 (1.27–2.89)	0.82 (0.61–1.09)	1.00	1.27 (0.98–1.64)	1.26 (0.85–1.86)	2.04 (1.30–3.18)
The association of nocturnal sleep duration (in hours) and ICH; odds ratio (95% CI)							
Model	<5	5	6	7	8	9	>9
Model 1 ^a	11.61 (3.50–38.55)	3.65 (1.92–6.92)	1.07 (0.71–1.62)	1.00	1.25 (0.84–1.85)	2.16 (1.22–3.82)	3.15 (1.56–6.39)
Model 2 ^b	9.12 (2.57–32.34)	2.84 (1.41–5.74)	1.35 (0.85–2.15)	1.00	1.17 (0.77–1.79)	2.13 (1.17–3.88)	2.60 (1.23–5.52)
Model 3 ^c	5.01 (0.86–29.34)	1.48 (0.63–3.49)	1.60 (0.89–2.87)	1.00	0.98 (0.60–1.61)	2.15 (1.10–4.21)	2.79 (1.23–6.33)
Model 4 ^d	8.23 (0.95–71.63)	2.22 (0.83–5.94)	1.76 (0.91–3.39)	1.00	0.95 (0.55–1.65)	1.99 (0.94–4.21)	2.71 (1.10–6.65)

Abbreviations: AHEI = Alternative Healthy Eating Index; BP = blood pressure; ICH = intracranial hemorrhage; mRS = modified Rankin scale; OSA = obstructive sleep apnea.

^a Univariate (conditional).

^b Adjusted for occupation, age, marital status, and preadmission mRS (conditional).

^c Adjusted for occupation, age, marital status, preadmission mRS, alcohol consumption, smoking history, leisure physical activity, total AHEI score, waist-to-hip ratio, body mass index (kg/m²), depressive symptoms, and global stress (conditional).

^d Adjusted for occupation, age, marital status, mRS at baseline, alcohol consumption, smoking history, leisure physical activity, total AHEI score, waist-to-hip ratio, body mass index (kg/m²), depressive symptoms, global stress, history of hypertension or adjusted BP >140/90 mm Hg at admission, a history of diabetes or hemoglobin A1c ≥6.5%, a history of atrial fibrillation/flutter, and a diagnosis of OSA (conditional).

quality alone remained significantly associated with an increased odds of stroke (Figure 2).

Symptoms of OSA

Self-reported snoring (OR 1.91, 95% CI 1.62–2.24), snorting (OR 2.64, 95% CI 2.17–3.20), and breathing cessation (OR 2.87, 95% CI 2.28–3.60) were associated with statistically significant increased odds of all stroke in the primary model, maintaining significance with all further adjustment. We observed a similar magnitude of association for responding “do not know” as responding positively for these symptoms (Figure 3). An OSA score of 2–3 was associated with a significantly increased odds of all stroke (OR 2.67, 95% CI 2.25–3.15), ICH (OR 4.07, 95% CI 2.73–6.08), and ischemic stroke (OR 2.39, 95% CI 1.98–2.89), in the primary model, maintaining significance with subsequent adjustment. Odds of ICH vs ischemic stroke did not differ significantly in case-case analysis ($p = 0.23$).

Sleep Disturbance Symptom Burden

In the analysis of Sleep Disturbance Symptom Burden, an increasing number of symptoms were associated with a

graded increase in stroke risk (2–3: OR 1.63, 95% CI 1.36–1.96; 4–5: OR 3.08, 95% CI 2.49–3.80; and >5: OR 5.38, 95% CI 4.03–7.18), with reference 0–1, in the primary model (Figure 4, eTable 5, links.lww.com/WNL/C721). Findings were also consistent for ischemic stroke (>5: OR 5.06, 95% CI 3.67–6.97) and ICH (>5: OR 8.36, 95% CI 4.05–17.26) (eTable 5, eFigure 3). Odds of ICH and ischemic stroke did not differ in case-case analysis ($p = 0.73$). Results for Sleep Disturbance Symptom Burden with OSA symptoms not included in score calculation are outlined in the eAppendix (eTable 6).

Hour of Stroke Onset and Wake-up Stroke


When cases/matched controls were divided into hour-of-onset categories and wake-up status categories (eFigure 4, links.lww.com/WNL/C721), individual estimates were highest in the night-time subgroup and the wake-up subgroup for both short sleep duration and Sleep Disturbance Symptom Burden of >5 (eTables 7–10). Differences were less pronounced for long sleep duration, and estimates in the OSA score of 2–3 category were higher in the morning and wake-up subgroups (eTables 7 and 8, eTables 11 and 12). CIs

Figure 2 Odds of All Stroke for Poor or Fair Sleep Quality, Sleep-onset Latency, Waking More Than Once, and Napping Status

A. Fair or bad sleep quality (good)*

Model OR (95% CI)


Model 1	1.73 (1.53–1.97)
Model 2	1.52 (1.32–1.75)
Model 3	1.35 (1.15–1.58)
Model 4	1.20 (1.00–1.42)



B. Sleep-onset latency present (absent)*

Model OR (95% CI)


Model 1	1.55 (1.35–1.78)
Model 2	1.32 (1.13–1.55)
Model 3	1.05 (0.88–1.26)
Model 4	0.96 (0.79–1.18)



C. Waking more than once (waking once or fewer)*

Model OR (95% CI)


Model 1	1.61 (1.42–1.83)
Model 2	1.33 (1.15–1.53)
Model 3	1.16 (0.99–1.36)
Model 4	1.00 (0.84–1.19)



D. Combination of napping duration (short: ≤1 hour, long: >1 hour) and napping plan (planned or unplanned) (no nap)*

Napping type Model OR (95% CI)

Napping type	Model	OR (95% CI)
Long unplanned	Model 1	2.88 (2.05–4.04)
Long planned		1.78 (1.40–2.26)
Short unplanned		1.37 (1.11–1.70)
Short planned		0.82 (0.70–0.97)
Long unplanned	Model 2	2.46 (1.69–3.57)
Long planned		1.67 (1.27–2.20)
Short unplanned		1.32 (1.04–1.68)
Short planned		0.91 (0.76–1.08)
Long unplanned	Model 3	2.05 (1.36–3.07)
Long planned		1.38 (1.01–1.88)
Short unplanned		1.14 (0.88–1.48)
Short planned		0.90 (0.74–1.10)
Long unplanned	Model 4	1.65 (1.06–2.57)
Long planned		1.42 (1.00–2.00)
Short unplanned		1.02 (0.77–1.36)
Short planned		0.87 (0.71–1.08)



Adjustment models are as follows: model 1: univariate (conditional); model 2: adjusted for occupation, age, marital status, and mRS at baseline (conditional); model 3: adjusted for occupation, age, marital status, mRS at baseline, alcohol consumption, smoking history, leisure physical activity, total AHEI score, waist-to-hip ratio, body mass index (kg/m²), depressive symptoms, and global stress (conditional); model 4: adjusted for occupation, age, marital status, mRS at baseline, alcohol consumption, smoking history, leisure physical activity, total AHEI score, waist-to-hip ratio, body mass index (kg/m²), depressive symptoms, global stress, a history of hypertension or adjusted BP >140/90 mm Hg at admission, a history of diabetes or hemoglobin A1c ≥6.5%, a history of atrial fibrillation/flutter, and a diagnosis of OSA (conditional). *For all panels (A–D), the reference level for each individual sleep parameter is displayed in brackets. AHEI = Alternative Healthy Eating Index; BP = blood pressure; mRS = modified Rankin scale; OR = odds ratio; OSA = obstructive sleep apnea.

crossed, however, and differences were not statistically significant in case-case analysis, other than for short sleep duration, which was associated with an increased odds of night time vs morning stroke ($p = 0.04$; eTable 13).

Interaction of Sleep Symptoms

We observed a significant interaction between sleep duration and snoring ($p = 0.002$), where estimates in the primary model were highest in snorers with short sleep duration (OR 4.04, 95% CI 3.12–5.25) and lowest in nonsnorers with long


sleep duration (OR 1.39, 95% CI 1.13–1.69) (eTable 14, links.lww.com/WNL/C721). There was no significant interaction found between sleep duration and other individual sleep symptoms (eTable 15).

Interaction in Demographic Variables


An interaction was found between sleep duration and both ethnicity ($p < 0.001$) and region ($p < 0.001$). In the primary model, the association of short sleep duration with stroke was highest for South Asian ethnicity and South Asia and

Figure 3 Odds of All Stroke for Snoring, Snorting, Breathing Cessation, and OSA Score


A. Snoring — yes/don't know (no)*




B. Snoring or gasping — yes/don't know (no)*



C. Breathing cessation or choking — yes/don't know (no)*




D. OSA score 2-3 (0-1)* for odds of all stroke, ischemic stroke, and ICH



Panels A–C demonstrate odds of all stroke for symptoms of, or uncertainty surrounding, snoring, snorting, or gasping and breathing cessation, respectively. Panel D demonstrates the odds of all stroke, ischemic stroke, and ICH with a potential OSA score of 2–3. Adjustment models are as follows: model 1: univariate (conditional); model 2: adjusted for occupation, age, marital status, and mRS at baseline (conditional); model 3: adjusted for occupation, age, marital status, mRS at baseline, alcohol consumption, smoking history, leisure physical activity, total AHEI score, waist-to-hip ratio, body mass index (kg/m²), depressive symptoms, and global stress (conditional); model 4: adjusted for occupation, age, marital status, mRS at baseline, alcohol consumption, smoking history, leisure physical activity, total AHEI score, waist-to-hip ratio, body mass index (kg/m²), depressive symptoms, global stress, a history of hypertension or adjusted BP >140/90 mm Hg at admission, a history of diabetes or hemoglobin A1c ≥6.5%, a history of atrial fibrillation/flutter, and a diagnosis of OSA (conditional). *For all panels (a-d), the reference level for each individual sleep parameter is displayed in brackets. AHEI = Alternative Healthy Eating Index; BP = blood pressure; ICH = intracerebral hemorrhage; mRS = modified Rankin scale; OR = odds ratio; OSA = obstructive sleep apnea.

Figure 4 Sleep Disturbance Symptom Burden



(A) Cumulative number of sleep disturbance symptoms in cases and controls, where sleep disturbance symptoms include the following: sleeping for <6 or >7 hours at night, SOL, waking more than once, napping for >1 hour, unplanned napping, and presence or uncertainty surrounding snoring, snoring or gasping, and breathing cessation or choking. (B) Odds of all stroke in sleep disturbance symptom number categories. OR presented on a log scale. Model 1 is univariate (conditional); model 2 adjusts for occupation, age, marital status, and mRS at baseline (conditional); model 3 adjusts for occupation, age, marital status, mRS at baseline, alcohol consumption, smoking history, leisure physical activity, total AHEI score, waist-to-hip ratio, body mass index (kg/m²), depressive symptoms, and global stress (conditional); model 4 adjusts for occupation, age, marital status, mRS at baseline, alcohol consumption, smoking history, leisure physical activity, total AHEI score, waist-to-hip ratio, body mass index (kg/m²), depressive symptoms, global stress, a history of hypertension or adjusted BP >140/90 mm Hg at admission, a history of diabetes or hemoglobin A1c ≥6.5%, a history of atrial fibrillation/flutter, and a diagnosis of OSA (conditional). AHEI = Alternative Healthy Eating Index; BP = blood pressure; mRS = modified Rankin scale; OR = odds ratio; OSA = obstructive sleep apnea; SOL = sleep-onset latency.

nonsignificant for Chinese ethnicity and China (eTable 16 and 17, eFigure 5, links.lww.com/WNL/C721). The association between long sleep duration and stroke remained significant in all ethnicity and region subgroups examined (eTable 16 and 17, eFigure 5). There was no significant interaction between sleep duration and age or sex (eTable 15).

Sensitivity Analysis

The source of information for cases (i.e., patient or proxy) did not materially alter findings for the sleep domains (eTable 18, links.lww.com/WNL/C721). Magnitude of ORs were generally higher for community vs hospital controls, but directions of estimates were consistent by source of control, in the primary model (eTables 19 and 20). Additional adjustment for household income did not materially change results (eTable 21).

Discussion

In this large international case-control study, we found a significant association between sleep impairments and risk of acute stroke. The odds of acute stroke were increased with short and long sleep duration, poor sleep quality, symptoms of OSA (snoring, snorting, and breathing cessation) and prolonged napping, after an extensive adjustment. The magnitude of association was additive, with a graded increase in odds of acute stroke, for cumulative increase in sleep symptoms, with consistent findings for ischemic stroke and ICH. Impairments in sleep domains associated with an increased risk of stroke were common and may represent important modifiable targets for stroke prevention interventions.

Associations between acute stroke and both short and long sleep duration have been reported in previous observational research.²⁰ In our study, there was a higher magnitude of association for short sleep duration, compared with long duration, on univariate analysis. However, after adjustment for coexisting risk factors, there was more marked attrition of the OR for short sleep duration. This suggests that confounders and mediators of these associations differ and that long sleep duration is more likely to have an independent association with acute stroke. In addition, the association for long sleep duration was found more consistently in different ethnicities and regions. This is complimentary to previous research, where associations have been more consistent for long sleep duration.⁹⁻¹¹ The mechanisms underlying this association could be influenced by BP surges associated with sleep architecture changes, for example, or relate to lack of physiologic challenge.²¹⁻²³ The relationship, however, may also be subject to residual universal confounding because long sleep duration may represent an epiphenomenon of comorbidity, older age, an otherwise sedentary lifestyle, and sedative use.²⁴⁻³⁰ A large proportion of participants in our study reported a nocturnal sleep duration within the range associated with stroke (<6 or >7 hours), making it an important potential risk factor for developing and evaluating public interventional studies.

Daytime sleeping (napping) has also been associated with an increased cardiovascular disease risk, particularly when prolonged, a finding that has challenged whether the common practice of siesta is healthy, with some conflicting results.^{12,24,27,30-33} The

Prospective Urban Rural Epidemiology study found that long duration napping was significantly associated with an increased risk of major cardiovascular events, in those who slept longer than 6 hours at night.³⁴ While, by contrast, we found no significant interaction with sleep duration, our findings, in another international setting, also suggest that the association with daytime napping is contextual. Long duration and unplanned napping are potential risk factors of stroke, but short duration and planned napping (e.g., siesta) were not associated with an increased risk, with the point estimate directionally suggestive of reduced odds. While our findings merit reproduction, they may help inform patient advice and management, where a prolonged nap may be harmful or representative of an underlying condition that requires further work-up, and a brief planned nap is less likely to increase the risk of stroke.

OSA is an established risk factor of acute ischemic stroke.³⁵ Our findings suggest that individual symptoms, which may represent OSA, are independently associated with stroke. This is complimentary to previous research, where snoring has been studied more frequently than snorting and breathing cessation.^{4,8,12,36} Patients with these self-reported symptoms of OSA may be at risk of stroke, independent of OSA severity and treatment, as has been suggested by a recent post hoc analysis of the SAVE trial.³⁶ Symptoms were common before stroke, in our study, where 59% of cases reported snoring, with 25% and 19% reporting snorting and breathing cessation, respectively. In addition, participants who were unsure about OSA-related symptoms had a similar increased odds of stroke as participants who endorsed these symptoms, suggesting a potential lack of awareness of OSA symptoms, rather than absence. This has important implications for questionnaire-based OSA screening in clinical practice and for conducting and interpreting clinical research in this context. While randomized controlled trials looking at positive airway pressure (PAP) in OSA have not reproduced evidence of lower cardiovascular events found in observational studies, there does seem to be a potential risk reduction when adherence is high and when PAP is used >4 hours per night.³⁷⁻³⁹ Given the frequency of symptoms in our study, and their relationship with stroke, exploring interventions that improve PAP adherence may be of benefit in primary stroke prevention. Identifying subgroups that are more likely to benefit, in addition to exploring alternative management strategies in patients with self-reported symptoms, are also important areas for future research.

Sleep quality, a self-reported subjective measure, was fair or poor in 46% of patients with acute stroke, in the preceding month. Further individual symptoms of frequent nocturnal awakening and SOL were also common, self-reported in 42% and 32% of cases, respectively. In our primary model, each of these sleep impairments was associated with an increased odds of acute stroke. However, after full adjustment, the latter 2 exposures were no longer significantly associated, similar to that observed in previous research.^{5,13,24,26,40,41}

These results imply that the association was confounded or mediated by cerebrovascular risk factors. The challenge in interpretation is to determine which of these adjustment variables are confounders and which reside along a potential causal pathway. For example, increased alcohol intake may cause disruptions in sleep quality, but impairments in sleep quality may result in increased use of alcohol, as a sedative.⁴² Our primary model, which did not include cerebrovascular risk factors, is expected to overestimate the independent association of sleep impairment and stroke risk, while the fully adjusted model likely underestimates the association, given that mediator variables are included. While numerous observational studies have reported bidirectional associations between sleep impairment and cerebrovascular risk factors, interventional clinical trials are required to determine whether improvement in sleep quality results in prospective changes in these factors and subsequent disease risk.⁴³ Few trials have been conducted to determine the effect of behavioral sleep interventions on cerebrovascular risk factors to date, with overall results being inconclusive.⁴⁴ The SLEPT trial, a phase IIb trial reported modest improvements in sleep quality with digital cognitive behavioral therapy (dCBT-I) but did not effect change in BP.⁴⁵ The results of the recent DISCO trial, however, where dCBT-I was associated with improvement in cognitive complaints, shows potential promise for this type of intervention in the cerebrovascular domain.⁴⁶

The graded association between the accumulation of these outlined sleep disturbance symptoms and stroke also has important implications from a public health and interventional trial perspective, particularly given the magnitude of estimates. This is an extensive study of sleep disturbance in this context, confirming previous findings in a limited amount of previous studies.^{4,5,41} Even if the relationship is not causal, those with multiple sleep disturbance symptoms should be thought of as at high risk of stroke and important targets for primary prevention studies involving both traditional risk factor management and interventions for sleep disturbance.

Our study has a few potential limitations. First, sleep symptoms were ascertained through subjective reporting, and validated tools/scores were not used to examine sleep quality/OSA symptoms and their association with stroke. Our assessments of sleep practices were similar to those of previous research in this area, however, and undertaking a prolonged sleep questionnaire would not have been possible in the context of this multifaceted study.²⁴ Second, because incident stroke may result in sleep disturbance, there is a risk of misclassification and recall bias.⁴⁷ Uncertainty surrounding OSA symptoms may be subject to similar biases, with stroke patients potentially more likely to answer “do not know.” Efforts taken to reduce the risk of these biases included recruiting cases within 72 hours of hospital admission and asking about sleep over a short time frame. Prospective cohort studies in this area have generally asked about sleep practices over a longer time frame. Because sleep can change

over time, our shorter time frame may have resulted in more accurate sleep symptom reporting.^{24,48} In addition, our results may be partially due to trigger effects of sleep disturbance on stroke, given the shorter time frame. Findings in relation to risk of night time and wake-up stroke may also be suggestive of this. Third, there may be a risk of healthy volunteer bias among community controls. In an effort to combat this, however, some hospital/outpatient controls were recruited. Given the findings of our sensitivity analysis, this inclusion likely biased our findings toward the null, underestimating the odds of stroke associated with sleep symptoms in a healthy community setting, with results more likely reflective of the true global population risk. Fourth, subgroup analyses were limited by participant numbers, and associations between sleep duration and stroke in different regions/ethnicities, for example, could not be fully assessed. Finally, despite extensive adjustment, residual confounding cannot be excluded. We were also unable to adjust for shift work or sedative use, and levels of diagnosed OSA were low.

In conclusion, our results suggest that individual and cumulative symptoms of sleep disturbance may be important modifiable risk factors of stroke and/or their presence identifies individuals at an increased risk of stroke. Our findings also suggest a complex relationship of sleep impairment, intermediate cerebrovascular risk factors, and stroke risk. Given that individual sleep disturbance symptoms were common and associated with an increased odds of stroke, interventional studies in patients with high sleep disturbance burden, and in those with individual sleep symptoms, should be considered a priority research target in the global effort to reduce stroke incidence.

Study Funding

The INTERSTROKE study is funded by the Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Canadian Stroke Network, Swedish Research Council, Swedish Heart and Lung Foundation, and The Health & Medical Care Committee of the Regional Executive Board, Region Västra Götaland, and through unrestricted grants from several pharmaceutical companies with major contributions from Astra Zeneca, Boehringer Ingelheim (Canada), Pfizer (Canada), MERCK, Sharp and Dohme, Swedish Heart and Lung Foundation, UK Chest, and UK Heart and Stroke.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures.

Publication History

Received by *Neurology* August 7, 2022. Accepted in final form February 16, 2023. Submitted and externally peer reviewed. The handling editor was Associate Editor Barbara Jobst, MD, PhD, FAAN.

Appendix 1 Authors

Name	Location	Contribution
Christine Eileen Mc Carthy, MSc	Department of Medicine, University of Galway, Ireland	Drafting/revision of the article for content, including medical writing for content; analysis or interpretation of data
Salim Yusuf, DPhil	Department of Medicine, Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
Conor Judge, PhD	Department of Medicine, University of Galway, Ireland	Drafting/revision of the article for content, including medical writing for content; analysis or interpretation of data
Alberto Alvarez-Iglesias, PhD	Department of Medicine, University of Galway, Ireland	Drafting/revision of the article for content, including medical writing for content; analysis or interpretation of data
Graeme J. Hankey, MBBS, MD, FRACP	School of Medicine and Pharmacology, Faculty of Health and Medical Sciences, University of Western Australia, Perth	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
Shahram Oveisgharan, MD	Department of Medicine, Rush Alzheimer Disease Research Center in Chicago, IL	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
Albertino Damasceno, MD	Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
Helle Klingenberg Iversen, MD	Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
Annika Rosengren, MD	Department of Molecular and Clinical Medicine, University of Gothenburg and Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
Alvaro Avezum, MD	Department of Medicine, International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
Patricio Lopez-Jaramillo, PhD	Department of Medicine, Instituto de Investigaciones MASIRA, Universidad de Santander, Bucaramanga, Colombia	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
Denis Xavier, MD	Department of Medicine, St John's Medical College and Research Institute, Bangalore, India	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data

Continued

Appendix 1 (continued)

Name	Location	Contribution
Xingyu Wang, PhD	Department of Medicine, Beijing Hypertension League Institute, China	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
Sumathy Rangarajan, MSc	Department of Medicine, Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
Martin O'Donnell, PhD	Department of Medicine, University of Galway, Ireland	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; and analysis or interpretation of data

Appendix 2 Coinvestigators

Coinvestigators are listed at links.lww.com/WNL/C722.

References

1. Ramar K, Malhotra RK, Carden KA, et al. Sleep is essential to health: an American Academy of Sleep Medicine position statement. *J Clin Sleep Med*. 2021;17(10):2115-2119. doi:10.5664/jcs.m.9476
2. Bassetti CLA, Randerath W, Vignatelli L, et al. EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke. *Eur J Neurol*. 2020;27(7):1117-1136. doi:10.1111/ene.14201
3. Khot SP, Morgenstern LB. Sleep and stroke. *Stroke*. 2019;50(6):1612-1617. doi:10.1161/STROKEAHA.118.023553
4. Elwood P. Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort. *J Epidemiol Commun Health*. 2006;60(1):69-73. doi:10.1136/jech.2005.039057
5. Fan M, Sun D, Zhou T, et al. Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants. *Eur Heart J*. 2020;41(11):1182-1189. doi:10.1093/eurheartj/ehz849
6. Jin X, Chen H, Li Y, et al. Association between daytime napping and stroke: a dose-response meta-analysis. *J Sleep Res*. 2021;30(5):e13366. doi:10.1111/jsr.13366
7. Hu S, Lan T, Wang Y, Ren L. Individual insomnia symptom and increased hazard risk of cerebrovascular diseases: a meta-analysis. *Front Psychiatry*. 2021;12:654719. doi:10.3389/fpsy.2021.654719
8. Li M, Li K, Zhang XW, Hou WS, Tang ZY. Habitual snoring and risk of stroke: a meta-analysis of prospective studies. *Int J Cardiol*. 2015;185:46-49. doi:10.1016/j.ijcard.2015.03.112
9. Li W, Wang D, Cao S, et al. Sleep duration and risk of stroke events and stroke mortality: a systematic review and meta-analysis of prospective cohort studies. *Int J Cardiol*. 2016;223:870-876. doi:10.1016/j.ijcard.2016.08.302
10. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. *Sleep*. 2010;33(5):585-592. doi:10.1093/sleep/33.5.585
11. Yin J, Jin X, Shan Z, et al. Relationship of sleep duration with all-cause mortality and cardiovascular events: a systematic review and dose-response meta-analysis of prospective cohort studies. *J Am Heart Assoc*. 2017;6(9):e005947. doi:10.1161/JAHA.117.005947
12. Wen Y, Pi FH, Guo P, et al. Sleep duration, daytime napping, markers of obstructive sleep apnea and stroke in a population of southern China. *Sci Rep*. 2016;6(1):34689. doi:10.1038/srep34689
13. Helbig AK, Stöckl D, Heier M, Ladwig KH, Meisinger C. Symptoms of insomnia and sleep duration and their association with incident strokes: findings from the Population-Based MONICA/KORA Augsburg Cohort Study. *PLoS One*. 2015;10(7):e0134480. doi:10.1371/journal.pone.0134480
14. O'Donnell M, Xavier D, Diener C, et al. Rationale and design of INTERSTROKE: a global case-control study of risk factors for stroke. *Neuroepidemiology*. 2010;35(1):36-44. doi:10.1159/000306058
15. Ikehara S, Iso H, Date C, et al. Association of sleep duration with mortality from cardiovascular disease and other causes for Japanese men and women: the JACC study. *Sleep*. 2009;32(3):295-301. doi:10.1093/sleep/32.3.295

16. Kim Y, Wilkens LR, Schembre SM, Henderson BE, Kolonel LN, Goodman MT. Insufficient and excessive amounts of sleep increase the risk of premature death from cardiovascular and other diseases: the Multiethnic Cohort Study. *Prevent Med*. 2013;57(4):377-385. doi:10.1016/j.ypmed.2013.06.017
17. Smyth A, Teo KK, Rangarajan S, et al. Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. *Lancet*. 2015;386(10007):1945-1954. doi:10.1016/S0140-6736(15)00235-4
18. Chiuve SE, Fung TT, Rimm EB, et al. Alternative dietary indices both strongly predict risk of chronic disease. *J Nutr*. 2012;142(6):1009-1018. doi:10.3945/jn.111.157222
19. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing; 2013. [R-project.org/](https://www.R-project.org/).
20. Kwok CS, Kontopantelis E, Kuligowski G, et al. Self-reported sleep duration and quality and cardiovascular disease and mortality: a dose-response meta-analysis. *J Am Heart Assoc*. 2018;7(15):e008552. doi:10.1161/JAHA.118.008552
21. Somers VK, Dyken ME, Mark AL, Abboud FM. Sympathetic-nerve activity during sleep in normal subjects. *N Engl J Med*. 1993;328(5):303-307. doi:10.1056/NEJM199302043280502
22. Åkerstedt T, Schwarz J, Gruber G, Theorell-Haglöw J, Lindberg E. Short sleep—poor sleep? A polysomnographic study in a large population-based sample of women. *J Sleep Res*. 2019;28(4):e12812. doi:10.1111/jsr.12812
23. Grandner MA, Drummond SPA. Who are the long sleepers? Towards an understanding of the mortality relationship. *Sleep Med Rev*. 2007;11(5):341-360. doi:10.1016/j.smrv.2007.03.010
24. Zhou L, Yu K, Yang L, et al. Sleep duration, midday napping, and sleep quality and incident stroke: the Dongfeng-Tongji cohort. *Neurology*. 2020;94(4):e345-e356. doi:10.1212/WNL.00000000000008739
25. Pan A, De Silva DA, Yuan JM, Koh WP. Sleep duration and risk of stroke mortality among Chinese adults: Singapore Chinese health study. *Stroke*. 2014;45(6):1620-1625. doi:10.1161/STROKEAHA.114.005181
26. Ji A, Lou H, Lou P, et al. Interactive effect of sleep duration and sleep quality on risk of stroke: an 8-year follow-up study in China. *Sci Rep*. 2020;10(1):8690. doi:10.1038/s41598-020-65611-y
27. von Ruesten A, Weikert C, Pietze I, Boeing H. Association of sleep duration with chronic diseases in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. *PLoS One*. 2012;7(1):e30972. doi:10.1371/journal.pone.0030972
28. Kawachi T, Wada K, Nakamura K, et al. Sleep duration and the risk of mortality from stroke in Japan: the Takayama Cohort Study. *J Epidemiol*. 2016;26(3):123-130. doi:10.2188/jea.JE20140272
29. Song Q, Liu X, Zhou W, et al. Long sleep duration and risk of ischemic stroke and hemorrhagic stroke: the Kailuan Prospective Study. *Sci Rep*. 2016;6(1):33664. doi:10.1038/srep33664
30. Li X, Pang X, Liu Z, et al. Joint effect of less than 1 h of daytime napping and 7 to 8 h of night sleep on the risk of stroke. *Sleep Med*. 2018;52:180-187. doi:10.1016/j.sleep.2018.05.011
31. Tanabe N, Iso H, Seki N, et al. Daytime napping and mortality, with a special reference to cardiovascular disease: the JACC study. *Int J Epidemiol*. 2010;39(1):233-243. doi:10.1093/ije/dyp327
32. Mohammad Y. Siesta and risk for ischemic stroke: results from a case-control study. *Medicina*. 2020;56(5):222. doi:10.3390/medicina56050222
33. Yan B, Jin X, Li R, et al. Association of daytime napping with incident stroke in middle-aged and older adults: a large community-based study. *Eur J Neurol*. 2020;27(6):1028-1034. doi:10.1111/ene.14197
34. Wang C, Bangdiwala SI, Rangarajan S, et al. Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries. *Eur Heart J*. 2019;40(20):1620-1629. doi:10.1093/eurheartj/ehy695
35. Dong JY, Zhang YH, Qin LQ. Obstructive sleep apnea and cardiovascular risk: meta-analysis of prospective cohort studies. *Atherosclerosis*. 2013;229(2):489-495. doi:10.1016/j.atherosclerosis.2013.04.026
36. Li J, McEvoy RD, Zheng D, et al. Self-reported snoring patterns predict stroke events in high-risk patients with OSA: post hoc analyses of the SAVE study. *Chest*. 2020;158(5):2146-2154. doi:10.1016/j.chest.2020.05.615
37. Li J, Zheng D, Loffler KA, et al. Sleep duration and risk of cardiovascular events: the SAVE study. *Int J Stroke*. 2020;15(8):858-865. doi:10.1177/1747493020904913
38. Lin HJ, Yeh JH, Hsieh MT, Hsu CY. Continuous positive airway pressure with good adherence can reduce risk of stroke in patients with moderate to severe obstructive sleep apnea: an updated systematic review and meta-analysis. *Sleep Med Rev*. 2020;54:101354. doi:10.1016/j.smrv.2020.101354
39. Peker Y, Thunström E, Glantz H, Eulenburg C. Effect of obstructive sleep apnea and CPAP treatment on cardiovascular outcomes in acute coronary syndrome in the RICCADSA trial. *J Clin Med*. 2020;9(12):4051. doi:10.3390/jcm9124051
40. Zhang S, Chang C, Zhang J, Song B, Fang H, Xu Y. Correlation analysis of sleep quality and youth ischemic stroke. *Behav Neurol*. 2014;2014:1-6. doi:10.1155/2014/246841
41. Zheng B, Yu C, Lv J, et al. Insomnia symptoms and risk of cardiovascular diseases among 0.5 million adults: a 10-year cohort. *Neurology*. 2019;93(23):e2110-e2120. doi:10.1212/WNL.00000000000008581
42. Haario P, Rahkonen O, Laaksonen M, Laahela E, Lallukka T. Bidirectional associations between insomnia symptoms and unhealthy behaviours. *J Sleep Res*. 2013;22(1):89-95. doi:10.1111/j.1365-2869.2012.01043.x
43. Mc Carthy CE. Sleep disturbance, sleep disorders and Co-morbidities in the care of the older person. *Med Sci*. 2021;9(2):31. doi:10.3390/medsci9020031
44. Li PW, Yu DSF, Chong SOK, Lin RSY. A systematic review on the effects of nonpharmacological sleep interventions on cardiometabolic risk or disease outcomes. *J Cardiovasc Nurs*. 2020;35(2):184-198. doi:10.1097/JCN.0000000000000662

45. McGrath ER, Espie CA, Power A, et al. Sleep to lower elevated blood pressure: a randomized controlled trial (SLEPT). *Am J Hypertens*. 2017;30(3):319-327. doi:10.1093/ajh/hpw132
46. Kyle SD, Hurry MED, Emsley R, et al. The effects of digital cognitive behavioral therapy for insomnia on cognitive function: a randomized controlled trial. *Sleep*. 2020;43(9):zsaa034. doi:10.1093/sleep/zsaa034
47. Hasan F, Gordon C, Wu D, et al. Dynamic prevalence of sleep disorders following stroke or transient ischemic attack: systematic review and meta-analysis. *Stroke*. 2021;52(2):655-663. doi:10.1161/STROKEAHA.120.029847
48. Leng Y, Cappuccio FP, Wainwright NWJ, et al. Sleep duration and risk of fatal and nonfatal stroke: a prospective study and meta-analysis. *Neurology*. 2015;84(11):1072-1079. doi:10.1212/WNL.0000000000001371